A uterine fibroid (or myoma) is a very common benign tumour of the uterine muscle; many cause no symptoms and only require monitoring. Treatment is discussed when it causes heavy periods, anaemia, pain, compression or difficulty conceiving. Among recent medical treatments, the combination of relugolix, estradiol and norethisterone acetate, in two randomised trials published in the New England Journal of Medicine, markedly reduced bleeding in 71 to 73% of women, compared with 15 to 19% on placebo.
A fibroid is a lump of muscular and fibrous tissue that develops in the wall of the uterus. It is benign: it is not a cancer and does not turn into cancer. Its growth depends on ovarian hormones (oestrogens and progesterone): it may grow during the reproductive years and generally shrinks after the menopause.

Fibroids are very common in women over 35. There may be just one or several, ranging from a few millimetres to more than 10 centimetres.
Their position is described by the FIGO classification, from 0 to 8:
This position matters more than size in understanding the symptoms.
Many fibroids are discovered by chance, during a routine examination or scan. When they do cause symptoms, these are mainly:
| Symptom | Fibroids most often responsible |
|---|---|
| Heavy, prolonged periods, clots | Submucosal (0 to 2), sometimes intramural |
| Tiredness, breathlessness due to anaemia | Consequence of heavy periods |
| Bleeding between periods | Submucosal |
| Pelvic heaviness, swollen abdomen | Large, intramural or subserosal |
| Frequent need to urinate | Anterior fibroid pressing on the bladder |
| Constipation, rectal discomfort | Posterior fibroid |
| Pelvic pain, painful periods | Variable; acute pain in the event of red degeneration or torsion |
| Difficulty conceiving, miscarriages | Mainly submucosal |
Bleeding or pain should not be attributed to a fibroid straight away: other causes (polyp, adenomyosis, hormonal disorder, abnormality of the endometrium) may coexist.
The key test is a pelvic ultrasound, by the abdominal and transvaginal routes. It shows the number of fibroids, their size and their FIGO type.
Depending on the situation, other tests may be offered:
The guidelines of the CNGOF published in 2023 (French College of Gynaecologists and Obstetricians) on abnormal uterine bleeding set out this diagnostic strategy and the management of fibroids according to their type.
Generally, no. An asymptomatic fibroid that does not affect fertility simply requires monitoring, clinical and by ultrasound, at intervals adapted to its size and how it changes.
A few situations lead to treatment being discussed despite the absence of discomfort:
As the menopause approaches, monitoring is often preferred: the fall in hormones generally leads to a reduction in the size of fibroids and in symptoms.
Medical treatments mainly aim to reduce bleeding. They do not make the fibroid disappear, and their effect generally stops when they are discontinued.
| Treatment | Main effect | Points to know |
|---|---|---|
| Tranexamic acid | Reduces menstrual blood loss | Taken only during periods; contraindicated in women with a history of thrombosis |
| Anti-inflammatories (NSAIDs) | Reduce bleeding and pain | Moderate effect |
| Progestogens, hormonal coil (levonorgestrel IUD) | Reduce bleeding | The IUD is less suitable if a fibroid distorts the cavity (risk of expulsion) |
| GnRH agonists (injections) | Put the ovaries at rest, reduce size | Effects of artificial menopause; short-term use, often before surgery |
| Relugolix combined with estradiol and norethisterone acetate (daily tablet) | Greatly reduces bleeding | The hormonal add-back limits hot flushes and bone loss; does not reduce the size of the fibroid |
| Ulipristal acetate | Formerly used to reduce bleeding and size | Use now very restricted because of rare cases of serious liver damage |
| Iron | Corrects anaemia | Always added if stores are low |
Relugolix combination therapy was evaluated in the LIBERTY 1 and 2 trials (770 women): 73% and 71% of patients had a reduction in bleeding to less than 80 ml per cycle and by at least 50%, compared with 19% and 15% on placebo. Bone density was comparable to placebo. However, the size of the fibroid itself did not decrease significantly. Prescribing conditions and reimbursement should be checked during the consultation.
Ulipristal acetate has had its use heavily restricted by the European health authorities following cases of serious liver damage. It is no longer a first-line treatment.
Combined oestrogen-progestogen contraception or menopausal hormone therapy is not contraindicated simply because of a fibroid.
When symptoms persist despite medical treatment, when that treatment is poorly tolerated or contraindicated, or when the fibroid is too large, an interventional treatment is discussed:
The choice depends on the FIGO type, the number and size of the fibroids, the wish for pregnancy, age and the patient’s preferences (see myomectomy or embolisation).
A fibroid is benign. There is, however, a rare malignant tumour of the uterine muscle, uterine sarcoma, which can look like a fibroid on ultrasound. Rapid growth, particularly after the menopause, an unusual appearance on MRI or bleeding after the menopause should lead to a specialist opinion. This rare possibility explains the precautions taken before certain surgical techniques such as morcellation.
Seek medical advice promptly or call 15 (SAMU) or 112 in France, or your local emergency number, in the event of:
Would you like a medical opinion?Appointments in Paris 16th or 5th, or by video consultation.
Book an appointmentIt does not disappear, but it often shrinks after the menopause, when the hormones that stimulate it fall. Before the menopause, it can remain stable for a long time.
Not necessarily. The decision is based on symptoms and impact rather than on size alone. Rapid growth does, however, justify a specialist opinion and often an MRI.
French guidelines do not contraindicate combined oestrogen-progestogen contraception in women with fibroids. The choice of contraception is discussed according to bleeding and other medical history.
Only certain fibroids, especially those that distort the uterine cavity, reduce the chances of pregnancy. This subject is covered in detail in the article fibroids, pregnancy and fertility.
The average waiting time for an appointment is one week to 10 days, except during holiday periods (Doctolib or 01 43 79 59 79). In the event of heavy bleeding with fainting, seek urgent care without waiting for the appointment.
A question about your situation?Appointments at the practice or by video consultation, usually within one week to 10 days.
Book an appointmentGeneral information article: it does not replace a medical consultation. In an emergency, call 15 or 112 in France, or your local emergency number.